In Value in Health Anouck Kluytmans, Marcia Tummers, Gert Jan van der Wilt and Janneke Grutters from the department for Health Evidence found, using a mixed methods approach, that although a recently developed medical technology was deemed ingenious by stakeholders, there was no underlying problem it could solve in its intended context (meniscus surgery). This suggests that in order to have value, developers should first explore the problem, before developing technology.
Although the relevance of both push and pull factors is acknowledged in models of innovation, needs, broadly defined, are rarely considered, whereas supply-driven innovation in publicly funded health systems carries the risk that it may not match the underlying problems experienced by patients and consumers.
To explore a mixed-methods, multistakeholder approach that focuses on pertinent problems when assessing the potential value of an innovation as applied to a case of surgical innovation in meniscus surgery.
Through interviews of stakeholders (n = 11) we sought to identify current problems of meniscus surgery in the Netherlands. On the basis of the subsequent problem definitions, we used stakeholder and literature input to quantify the room for improvement and stakeholder engagement to uncover possible barriers and facilitators to the implementation of the proposed innovation.
Despite being enthusiastic about the ingenuity of the proposed innovation and seeing some potential for cost saving, most stakeholders (n = 10) agreed that there are no major problems in current meniscus surgery meriting the innovation. They even discerned pragmatic barriers that would challenge the potential cost savings.
By adopting a problem-oriented multistakeholder approach to early health technology assessment, we were able to estimate the potential value of an innovation in its social context, finding that, beyond the initial enthusiasm, the proposed innovation was unlikely to resolve the problems distinguished by the stakeholders. We concluded that our multistakeholder, mixed-methods approach to early health technology assessment is feasible and helps foster more demand-driven innovations
Early Assessment of Proof-of-Problem to Guide Health Innovation.
Kluytmans A, Tummers M, van der Wilt GJ, Grutters
J. Value Health. 2019 May
Related news items
650,000 Euro funding for research into the phasing out of medication for leukaemia patients30 July 2020
With a 650,000 euro funding from ZonMw, researchers from the Haematology and Pharmacy departments can develop a medication phasing out strategy for patients with chronic myeloid leukaemia. This strategy will be tested in practice.read more
Increased role of patients after bowel cancer treatment30 July 2020
Approximately 14,000 patients get colorectal cancer every year. Almost all patients are operated on and monitored afterwards (follow-up). In 2019 Radboudumc started a new approach to follow-up research after the treatment of stage II/III colorectal cancer.read more
ERC Proof of Concept grant received by Ronald van Rij30 July 2020
Ronald van Rij, theme Infectious diseases and global health, received an ERC (European Research Council) Proof of Concept grant of 150,000 euros, in order to make arbovirus vaccines even safer.read more
Hypatia fellowship Call is open30 July 2020
The Hypatia fellowship round with the deadline 31 May has been canceled. Therefore, the next available deadline will be 27 September 2020. Radboudumc researchers are invited to scout young potentials to fill the strategic gaps within the research themes imbedded in RIHS and RIMLS.read more
Mihai Netea and colleagues published two papers back-to-back in The Journal of Clinical Investigation.29 July 2020
These back-to-back articles investigated the effect of BCG vaccination on trained immunity. The first article shows that BCG vaccination inhibits systemic inflammation, depending on gender. The second article demonstrates that the circadian rhythm influences the induction of trained immunity.read more
Genetic mutation reveals how coronavirus strikes TLR7 plays essential role in disease process28 July 2020
''Does a congenital immune defect play an important role in the defense against Coronavirus?'' This was published by Cas van der Made, Frank van der Veerdonk and Alexander Hoischen.read more